Inhibition of B16 melanoma growth and metastasis in C57BL mice by vaccination with a syngeneic endothelial cell line

Journal of Experimental and Clinical Cancer Research

Volumn 28, Issue 1, 2009, Pages

  Yoshiura, Kenta ^a   Nishishita, Toshihide ^b   Nakaoka, Takashi ^b   Yamashita, Naohide ^b   Yamashita, Naomi ^a  

^a MUSASHINO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CELL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; C57BL 6 MOUSE; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER MODEL; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ENDOTHELIUM CELL; HYBRIDOMA; IMMUNE RESPONSE; LUNG METASTASIS; MELANOMA B16; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME; ADOPTIVE IMMUNOTHERAPY; ANIMAL; C57BL MOUSE; CELL LINE; EXPERIMENTAL MELANOMA; IMMUNOLOGY; LUNG TUMOR; METASTASIS; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; ANTIBODY SPECIFICITY; CANCER VACCINES; CELL LINE; CELL LINE, TUMOR; ENDOTHELIAL CELLS; IMMUNOTHERAPY, ADOPTIVE; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC;

EID: 60849098452     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-28-13     Document Type: Article

References (29)

1. Carbonic anhydrase II is a tumor vessel endothelium-associated antigen targeted by dendritic cell therapy. K Yoshiura T Nakaoka T Nishishita K Sato A Yamamoto S Shimada T Saida Y Kawakami TA Takahashi H Fukuda S Imajoh-Ohmi N Oyaizu N Yamashita, Clin Cancer Res 2005 11 8201 8207 16299253
2. What is the evidence that tumors are angiogenesis dependent? J Folkman, J Natl Cancer Inst 1990 82 4 6 1688381
3. Mechanisms and future directions for angiogenesis-based cancer therapies. FA Scappaticci, J Clin Oncol 2002 20 3906 3927 12228212
4. Tumorigenesis and the angiogenic switch. G Bergers LE Benjamin, Nat Rev Cancer 2003 3 401 410 12778130
5. Tumour vascular targeting. D Neri R Bicknell, Nat Rev Cancer 2005 5 436 446 15928674
6. Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. YQ Wei MJ Huang L Yang X Zhao L Tian Y Lu JM Shu CJ Lu T Niu B Kang YQ Mao F Liu YJ Wen S Lei F Luo LQ Zhou F Peng Y Jiang JY Liu H Zhou QR Wang QM He F Xiao YY Lou XJ Xie Q Li Y Wu ZY Ding B Hu M Hu W Zhang, Proc Natl Acad Sci USA 2001 98 11545 11550 11553767
7. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. AG Niethammer R Xiang JC Becker H Wodrich U Pertl G Karsten BP Eliceiri RA Reisfeld, Nat Med 2002 8 1369 1375 12415261
8. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis. L Zhang D Yu DJ Hicklin JA Hannay LM Ellis RE Pollock, Cancer Res 2002 62 2034 2042 11929822
9. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. Y Li MN Wang H Li KD King R Bassi H Sun A Santiago AT Hooper P Bohlen DJ Hicklin, J Exp Med 2002 195 1575 1584 12070285
10. Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. JY Liu YQ Wei L Yang X Zhao L Tian JM Hou T Niu F Liu Y Jiang B Hu Y Wu JM Su YY Lou QM He YJ Wen JL Yang B Kan YQ Mao F Luo F Peng, Blood 2003 102 1815 1823 12750177
11. Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumor development. SM Plum JW Holaday A Ruiz JW Madsen WE Fogler AH Fortier, Vaccine 2000 19 1294 1303 11137269
12. Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice. QM He YQ Wei L Tian X Zhao JM Su L Yang Y Lu B Kan YY Lou MJ Huang F Xiao JY Liu B Hu F Luo Y Jiang YJ Wen HX Deng J Li T Niu JL Yang, J Biol Chem 2003 278 21831 21836 12651849
13. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. N Takahashi A Haba F Matsuno BK Seon, Cancer Res 2001 61 7846 7854 11691802
14. Immunotherapy of tumors with protein vaccine based on chicken homologous Tie-2. Y Luo YJ Wen ZY Ding CH Fu Y Wu JY Liu Q Li QM He X Zhao Y Jiang J Li HX Deng B Kang YQ Mao YQ Wei, Clin Cancer Res 2006 12 1813 1819 16551866
15. Identification of a novel membrane protein, HP59, with therapeutic potential as a target of tumor angiogenesis. C Fu S Bardhan ND Cetateanu BD Wamil Y Wang HP Yan E Shi C Carter C Venkov FM Yakes DL Page RS Lloyd RL Mernaugh CG Hellerqvist, Clin Cancer Res 2001 7 4182 4194 11751519
16. A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. R Xiang N Mizutani Y Luo C Chiodoni H Zhou M Mizutani Y Ba JC Becker RA Reisfeld, Cancer Res 2005 65 553 561 15695399
17. Active immunogene therapy of cancer with vaccine on the basis of chicken homologous matrix metalloproteinase-2. JM Su YQ Wei L Tian X Zhao L Yang QM He Y Wang Y Lu Y Wu F Liu JY Liu JL Yang YY Lou B Hu T Niu YJ Wen F Xiao HX Deng J Li B Kan, Cancer Res 2003 63 600 607 12566302
18. Immunogene therapy of tumors with a vaccine based on the ligand-binding domain of chicken homologous integrin beta3. YY Lou YQ Wei L Yang X Zhao L Tian Y Lu YJ Wen F Liu MJ Huang B Kang F Xiao JM Su QM He XJ Xie YQ Mao S Lei JY Liu F Lou LQ Zhou F Peng Y Jiang B Hu, Immunol Invest 2002 31 51 69 11990463
19. Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability. F Liao JF Doody J Overholser B Finnerty R Bassi Y Wu E Dejana P Kussie P Bohlen DJ Hicklin, Cancer Res 2002 62 2567 2575 11980651
20. A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth. L Holmgren E Ambrosino O Birot C Tullus N Veitonmaki T Levchenko LM Carlson P Musiani M Iezzi C Curcio G Forni F Cavallo R Kiessling, Proc Natl Acad Sci USA 2006 103 9208 9213 16754857
21. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. J Oliner H Min J Leal D Yu S Rao E You X Tang H Kim S Meyer SJ Han N Hawkins R Rosenfeld E Davy K Graham F Jacobsen S Stevenson J Ho Q Chen T Hartmann M Michaels M Kelley L Li K Sitney F Martin JR Sun N Zhang J Lu J Estrada R Kumar A Coxon S Kaufman J Pretorius S Scully R Cattley M Payton S Coats L Nguyen B Desilva A Ndifor I Hayward R Radinsky T Boone R Kendall, Cancer Cell 2004 6 507 516 15542434
22. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. YQ Wei QR Wang X Zhao L Yang L Tian Y Lu B Kang CJ Lu MJ Huang YY Lou F Xiao QM He JM Shu XJ Xie YQ Mao S Lei F Luo LQ Zhou CE Liu H Zhou Y Jiang F Peng LP Yuan Q Li Y Wu JY Liu, Nat Med 2000 6 1160 1166 11017149
23. Vaccination with autologous endothelium inhibits angiogenesis and metastasis of colon cancer through autoimmunity. Y Okaji NH Tsuno J Kitayama S Saito T Takahashi K Kawai K Yazawa M Asakage N Hori T Watanabe Y Shibata K Takahashi H Nagawa, Cancer Sci 2004 95 85 90 14720332
24. Vaccination with viable human umbilical vein endothelial cells prevents metastatic tumors by attack on tumor vasculature with both cellular and humoral immunity. XY Chen W Zhang S Wu F Bi YJ Su XY Tan JN Liu J Zhang, Clin Cancer Res 2006 12 5834 5840 17020991
25. Murine endothelial cell lines as models of tumor endothelial cells. J Walter-Yohrling S Morgenbesser C Rouleau R Bagley M Callahan W Weber BA Teicher, Clin Cancer Res 2004 10 2179 2189 15041739
26. Expression of endothelial cell IgG Fc receptors and markers on various cultures. L Pan RA Kreisle Y Shi, Chin Med J (Engl) 1999 112 157 161 11593585
27. Genes expressed in human tumor endothelium. B St Croix C Rago V Velculescu G Traverso KE Romans E Montgomery A Lal GJ Riggins C Lengauer B Vogelstein KW Kinzler, Science 2000 289 1197 1202 10947988
28. Combination of low-dose gemcitabine and recombinant quail vascular endothelial growth factor receptor-2 as a vaccine induces synergistic antitumor activities. JM Hou JY Liu L Yang X Zhao L Tian ZY Ding YJ Wen T Niu F Xiao YY Lou GH Tan HX Deng J Li JL Yang YQ Mao B Kan Y Wu Q Li YQ Wei, Oncology 2005 69 81 87 16088235
29. Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy. Y Okaji NH Tsuno M Tanaka S Yoneyama M Matsuhashi J Kitayama S Saito Y Nagura T Tsuchiya J Yamada J Tanaka N Yoshikawa T Nishikawa Y Shuno T Todo N Saito K Takahashi H Nagawa, Eur J Cancer 2008 44 383 390 18060766